Objectives: Prior to 2012, detection of major CHA had been based mainly on combined first trimester or integrated screening and ultrasound examinations. High-risk cases had been offered invasive diagnostics and karyotyping. The implementation of non-invasive prenatal screening (NIPS) might lead to a decrease of invasive tests causing lower accidental detection of other autosomal aberrations than trisomies 21,18,13 in the population. We tested the hypothesis, that the ratio of prenatally diagnosed CHA has been changed since the gradual implementation of NIPS after 2012. Methods: We used data from the National Registry of Congenital Anomalies including the individually collected data on prenatally diagnosed cases. We have analysed the prenatally diagnosed cases of all CHA (ICD-10 codes: Q90-Q99) during the 2012-2015 time period. The numbers were evaluated for the group of main autosomal trisomies and ''other'' CHA separately. The time trends were statistically evaluated using GraphPad InStat statistical software. Results: The number of invasive procedures, amniocenteses and chorion biopsies decreased from 11407 in the year 2012 to 7680 in 2015. A total of 575 cases of CHA were identified in 2012, of which 329 cases (57.5%) were trisomies 21, 18 and 13. In 2015, 577 cases of all CHA were identified, with major trisomies contributing 374 cases (64.8%). Thus there was no significant change in the proportion of group of major autosomal trisomies, compared to the ''other'' CHA (p>0.05). During the study period the total number of prenatally diagnosed CHA was 2369; major trisomies contributed 1462 cases (76.3%). Conclusions: We were not able to confirm, that the implementation of NIPS with consequent decrease of invasive procedures would lead to less recognition of other unbalanced CHA, that could also have severe phenotypical features for the fetus and/or infant. The overall ratio of prenatally diagnosed trisomies 21,13,18 and ''other'' autosomal aberrations remained unchanged.
Supported 
Methods:
We performed a validation of our set-up and evaluated technical, maternal and fetal characteristics of 'no-call' cases. NIPT analyses were performed on circulating cell-free DNA and Massive Parallel whole-genome Sequencing on a HiSeq1500 (Illumina). Bioinformatics were performed in samples with > 8 mio. reads using a pipeline for fetal fraction (SeqFF) and aneuploidy by WISECONDOR. Data analysis for aneuploidy and fetal sex were accepted in samples with a fetal fraction (FF) above 0.02 and 0.025, respectively. Results: Among 205 selected cases (incl. 73 aneuploidy cases), 13 lead to 'no-call' results (6%). In four euploid cases the reason was technical (BAD cluster) and in nine cases FF was below cut-off (0.02). The gestational age among 'no-calls' ranged from 12 weeks + 3 days to 15 weeks + 2 days. The number of reads ranged from 8 to 34 mio. In the group of 'no-calls' caused by low FF two cases had a maternal BMI>40, four cases had a BMI between 30 and 40, and three cases had a BMI<30. Furthermore, in the group of cases with low FF we found a high number of aneuploidy cases (T21=2, T18=4, T13=1, euploid=2). The Z-scores (ChrW) among the seven aneuploidy cases with a low FF ranged from 0.08 to 6 (cut-off=3). Two cases of T18 and one case of T13 had a Z-score >3 despite a low FF. If the fetal fraction had not been determined four aneuploidy cases might have been false negative. Conclusions: High maternal BMI and fetal aneuploidy highly influence the risk of a 'no-call' result. Therefore, labs performing NIPT in a population with a high number of obese women might have a higher 'no-call' rate. We found a high number of aneuploidy cases among 'no-calls'. Only T18 and T13 are described in the literature to have decreased FF. If we had not included determination of FF in our set-up, four cases might have been false negative.
